AAPGAscentage Pharma Group Inc.Signing up patients
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Relapsed/Refractory Acute Myeloid Leukaemia · Myeloid Malignancy
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 682 (planned)
- Started
- Sep 28, 2020
- Main results expected
- Sep 2028
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Limiting Toxicities (DLT)
Measured over: 28 days
Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)
Measured over: 28 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04501120 · record last updated 2026-04-29 · checked 2026-11-09 15:47 UTC